Status | Study |
Not yet recruiting |
Study Name: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Condition: Adenoid Cystic Carcinoma Adnexal Carcinoma Apocrine Carcin Date: 2016-11-30 Interventions: Other: Laboratory Biomarker Analysis |
Not yet recruiting |
Study Name: Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Condition: Columnar Cell Variant Thyroid Gland Papillary Carcinoma Follicular Variant Thyroid Gland Pap Date: 2016-11-23 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Condition: Acinar Cell Carcinoma Adrenal Cortex Carcinoma Adrenal Gla Date: 2016-07-13 Interventions: Procedure: Biospecimen Collection |
Active, not recruiting |
Study Name: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Condition: Ovarian Endometrioid Adenocarcinoma Ovarian Seromucinous Carcinoma Date: 2014-11-03 Interventions: Drug: Everolimus Given PO |
Recruiting |
Study Name: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition: Ovarian Brenner Tumor Ovarian Carcinosarcoma Ovarian Clear Date: 2014-03-28 Interventions: Drug: Gemcitabine Hydrochloride |
Active, not recruiting |
Study Name: Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Condition: Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Date: 2010-04-29 Interventions: Drug: Cediranib Maleate Given |
Active, not recruiting |
Study Name: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Condition: Adult Hepatocellular Carcinoma Advanced Adult Hepatocellular Carcinoma Date: 2009-11-06 Interventions: Biological: Bevacizumab Given |
Terminated |
Study Name: Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma Condition: Fallopian Tube Cancer Ovarian Cancer Peritoneal Cavity Can Date: 2008-04-03 Interventions: Drug: atrasentan hydrochloride |
Withdrawn |
Study Name: Research Study in Patients With Advanced Ovarian Epithelial Cancer Condition: Ovarian Serous Cystadenocarcinoma Ovarian Serous Surface Papillary Ade Date: 2003-01-27 Interventions: Genetic: Comparative Genomic Hybridization |